SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Apricus Biosciences
An SI Board Since September 2014
Posts SubjectMarks Bans Symbol
2026 18 0 APRI
Emcee:  mokelumne river Type:  Moderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
1901SL, I have the same nagging concerns. One thing we have to remember, very few imokelumne river-4/29/2016
1900MI great analyses. Thanks for your efforts to breakdown all that information. GrStrong Long-4/29/2016
1899This is just the tip of the iceberg if VitAROS gets approved in US , which meansapriluv-4/29/2016
1898good points James, and yes that is correct on Pascoe's comment I agree the eico20-4/29/2016
1897Eman, you may be right with all of them. I have tended to discount the collusiomokelumne river-4/29/2016
1896I suspect 3 possible problems with the UK, one - Takeda was waiting for the roomeico20-4/29/2016
1895Another point on the Ferring deal, Takeda was to provide $36.6M in sales milestomokelumne river-4/29/2016
1894We will see...it would be nice to see some approvals in Latin America for sure. phoenix_rising-4/29/2016
1893PR, it has always puzzled me why an outfit like Takeda, obviously a Japanese phamokelumne river-4/29/2016
1892Takeda paid $1.6m for Uk rights. Clearly they expected much better sales than tphoenix_rising-4/28/2016
1891Gang, I hate to ask.....does anyone know much Takeda paid for rights to Vitaros OldBoar-4/28/2016
1890On April 25, 2016, the Companys wholly-owned subsidiary, NexMed (U.S.A.), Inc. (apriluv-4/28/2016
1889very good analysis MI, a public statement regarding a Sandoz relaunch in Germaneico20-4/28/2016
1888Short interest dropped 44K shares to 2,834,145 shares. Hardly worth mentioning.mokelumne river-4/28/2016
1887Thanks for keeping us up to date with the I.R. non-response ( what's new? ) Mirror Image14/27/2016
1886James, I always value your opinion and in this case it's no different. ThankStrong Long-4/26/2016
1885SL, it is hard to argue with the fact that launches and rights did not move the mokelumne river-4/26/2016
1884James, it certainly could react in the manner you suggest...and I would be very Strong Long-4/26/2016
1883SL, the thing I don't understand is the sentiment that we are now years awaymokelumne river-4/26/2016
1882James, MI, good to hear that you guys are getting some nicely priced shares. I wStrong Long-4/26/2016
1881I suppose getting on Zack's strong buy list is something I should cheer aboumokelumne river-4/26/2016
1880Well PR, I sure hope you are wrong in your assessment. Apricus is a high risk bmokelumne river-4/26/2016
1879I still have a third of my shares left...just can't bring myself to sell thephoenix_rising-4/25/2016
1878OK PR, my OCD for wanting to own round numbers of shares kicked in. (I think thmokelumne river-4/25/2016
1877Sorry James, I meant MR and not MK. I was alluding to your statement that FDA apoldcoach19-4/22/2016
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News